Drug intelligence / Profile preview

olaptesed pegol + filgrastim

Development stage: Unknown
Lead developer: TME Pharma
Modality: Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Subcutaneous, Intravenous

Overview

Olaptesed pegol + filgrastim is an experimental combination regimen combining olaptesed pegol, a pegylated L-oligoribonucleotide inhibitor of the chemokine CXCL12, with filgrastim, a recombinant human granulocyte colony-stimulating factor (G-CSF). Olaptesed pegol functions by blocking the interaction between CXCL12 and its receptors (CXCR4/CXCR7), thereby disrupting the chemokine-mediated retention of hematopoietic and malignant cells within the bone marrow microenvironment, with intent to sensitize tumor cells to chemotherapy or other interventions. Filgrastim stimulates the production and mobilization of neutrophils and hematopoietic progenitor cells, reducing neutropenia and potentially enhancing stem cell mobilization for transplantation. This combination is under clinical investigation for its effects on mobilization of hematopoietic stem cells and for potential therapeutic benefit in oncology indications.

Brand names: NeupogenNivestymReleukoZarxioNypozi
Other names: olaptesed pegol + filgrastim

Targets

CXCR7 (CXC chemokine receptor 7)CXCL12 (C-X-C motif chemokine ligand 12)CXCR4 (C-X-C motif chemokine receptor 4)CSF3R (Granulocyte colony-stimulating factor receptor)

Beyond the preview

Go deeper on olaptesed pegol + filgrastim.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on olaptesed pegol + filgrastim.

Explore the full profile